Company profileMixed portfolio#175 of 1,318 in Pakistan10 DRAP alerts

Otsuka Pakistan Limited

Mixed portfolio · 75 pharmaceutical brands of 102 registrations

Ranked #1 of 11 companies in Solutions Affecting The Electrolyte Balance

102 registered products 75 pharmaceutical brands 78 distinct molecules 10 DRAP alerts
Part of this company's portfolio (“Nutritional Supplement / Multivitamin”) is registered under a broad DRAP category rather than distinct molecules, so the molecule count understates its true range.

Company overview

102
registered products
75
pharmaceutical brands
78
distinct molecules
11
therapeutic classes
10
DRAP alerts

Otsuka Pakistan Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 102 product registrations across 78 distinct molecules. It is the 175th largest registrant in Pakistan by product count, and ranks 1st of 11 in Solutions Affecting The Electrolyte Balance. Its portfolio is concentrated in Solutions Affecting The Electrolyte Balance and Amino Acid Solution. DRAP has issued 11 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Otsuka

51 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Solutions Producing Osmotic Diuresis 2
Electrolyte Solutions, Combination 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

15
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20251
202614

Top molecules by brand count

Nutritional Supplement / Multivitamin33 brands
Sodium6 brands
Chloride5 brands
Mannitol3 brands

Therapeutic classes

Solutions Affecting The Electrolyte Balance · 9Amino Acid Solution · 3Solutions Producing Osmotic Diuresis · 2Electrolyte Solutions, Combination · 2Other Analgesics And Antipyretics · 1Blood Conditions · 1Peripheral Vasodilators · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Gastro · 1Solutions For Parenteral Nutrition · 1Agents Against Amoebiasis And Other Protozoal Diseases · 1

Conditions treated

Liver/Kidney/Stone · 2Infusions · 2Blood Clot/Thrombotic Disorder · 1Ulcer/Reflux/Flatulence/Acidity · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official36 products · Rs 14.86 – Rs 264.97
DVAGO26 products · Rs 98.52 – Rs 6,736.39
Servaid7 products · Rs 377.83 – Rs 6,117
Median across source: Rs 177.93

Regulatory record

10 alerts in the DRAP feed we track.

129. Recall Alert(Class-I) – DIFAM Injection 3ml (Bosch Pharma) – Substandard
2026-01-14
120. Recall Alert (Class-I) – Drug Products (Human) Substandard by DTL Punjab.
2025-12-16
110. Recall Alert (Class-I) – Dexamex Injection (Batch # DX250017)
2025-11-17
Drug Safety Alert: Risks associated with the use of Valproic Acid in Women and Girls of Ch
2024-05-10
Rapid Alert; Drug Product: Falsified Defitelio 80mg/mL Injection identified in Neighboring
2023-09-12
Rapid Alert: Drug Product; Falsified Defitelio Infusion identified in the WHO Regions of E
2023-06-22
Recall Alert: Drug Product; Fenbar 50mg Tablets (Batch # 2752) by M/s Usawa Pharmaceutical
2023-01-26
Drug Safety Alert: Risk of Anaphylactic Reaction / Anaphylactic Shock with Diclofenac Sodi
2022-11-18

Competitive set

Companies whose registered portfolio overlaps most with this one.

Medipak (Pvt) Ltd36 shared molecules
GEOFMAN PHARMACEUTICALS23 shared molecules
FRONTIER DEXTROSE LIMITED21 shared molecules
SEARLE IV SOLUTION16 shared molecules
NEUTRO PHARMA (PVT) LTD.16 shared molecules
B. BRAUN PAKISTAN (PVT) LTD.14 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Medipak (Pvt) Ltd holds 63 molecules not in this portfolio
000 I.UAdenosine Containing Eye PrepsAdernaline 1MgAprepitantAscorbic AcidAtorvastatin
GEOFMAN PHARMACEUTICALS holds 60 molecules not in this portfolio
AmikacinAmoxicillinAmoxycillinArtemetherAtorvastatinAzithromycin
SIZA INTERNATIONAL (PVT) LTD. holds 75 molecules not in this portfolio
AcyclovirAlbendazoleAlbuterolAllopurinolAllopurinol TabAmikacin

Get the full profile for Otsuka

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.